Lilly marks Kenosha expansion for Zepbound and Mounjaro production
The Kenosha plant already fills injectable tirzepatide doses, and Lilly says the expansion adds capacity amid rising demand, though the added output has not been disclosed.
Eli Lilly is marking the opening of an expansion at its Kenosha County, Wisconsin site, an injectable medicine production plant that makes the company's tirzepatide drugs Zepbound and Mounjaro [1].
Serafino Fabiano, associate vice president and site lead for the Kenosha facility, described the timeline on a WisBusiness podcast. "In 18 months, we were able to move from the acquisition to the FDA approval and make medicine for our patients," he said [1]. Lilly acquired the property in 2024 and announced plans for a $3 billion investment in Wisconsin for the injectable medicine production site [1].
Fabiano said the plant has been producing Zepbound and Mounjaro since November of last year [1]. He described Lilly's injectable strategy as supporting treatments for people with diabetes, obesity and other conditions [1].
The site is expected to support 750 "highly skilled jobs" such as operators, technicians, engineers and scientists, while the construction phase alone will support thousands of jobs over multiple years, according to the podcast [1]. Lilly is also hiring local contractors for security, groundskeeping and other services [1].
On the broader buildout, Fabiano said Lilly has committed more than $50 billion since 2020 to expand its manufacturing capacity around the world [1]. A Scientist Live report published September 7, 2026, describes the figure differently, saying Lilly will more than double its US manufacturing investments since 2020, surpassing US$50 billion, and plans four new sites — three for active pharmaceutical ingredients and one to expand its injectable manufacturing network [2]. That report says the investment is expected to generate over 3,000 high-skilled jobs and nearly 10,000 construction jobs, and that Lilly's prior domestic commitments between 2020 and 2024 totaled $23 billion, a list that includes the Kenosha acquisition and expansion [2]. The two accounts differ on scope: Fabiano described worldwide manufacturing spending, while the Scientist Live report frames the total as US investment [1][2].
Lilly has not published incremental output figures for the Kenosha expansion, and no production volumes for the site have been reported [1][2].
Why it matters for patients
Zepbound and Mounjaro are injected medicines, so they depend on plants that can fill and finish sterile doses. Lilly says the Wisconsin investment comes amid rising demand for these drugs, and Fabiano said the company aims to "be sure we can reliably provide today's medicine" while preparing for later products [1].
What that means for any individual prescription has not been disclosed. Lilly has not said how many additional doses the Kenosha expansion can produce, so it has not been reported how much the added capacity changes overall supply of tirzepatide [1][2]. The announcement also does not address pricing, insurance coverage or availability at a particular pharmacy, and neither account says whether supply currently meets demand [1][2].
What happens next
Construction at the site is continuing. "If you drive by our site you will see cranes still being raised," Fabiano said, adding, "We are at the beginning of the journey" [1]. Lilly has not disclosed a completion date or output target for the Kenosha expansion, and no timeline for the four additional sites described by Scientist Live has been reported [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.